Carfilzomib and Belatacept for Desensitization (ADAPT)
Measuring the Impact of Carfilzomib and Belatacept on Allogeneic Desensitization in Prospective Kidney Transplant Recipients (ITN089ST)
Sponsor: Bristol-Myers Squibb
This PHASE1/PHASE2 trial investigates Highly Sensitized Prospective Kidney Transplant Recipients and is currently ongoing. Bristol-Myers Squibb leads this study, which shows 12 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2025 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Mar 2025 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2024 — Mar 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 7 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2023 — Feb 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2022 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Immune Tolerance Network (ITN)
- National Institute of Allergy and Infectious Diseases (NIAID)
- PPD Development, LP
- Rho Federal Systems Division, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .